[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].

@article{Han2011AMR,
  title={[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].},
  author={Baohui Han and Qing-yu Xiu and Huimin Wang and Jie Shen and Ai-qin Gu and Yi Luo and Chunxue Bai and Shuliang Guo and Wenchao Liu and Zhi-Xiang Zhuang and Yang Zhang and Yi-zhuo Zhao and Li-yan Jiang and Chun-lei Shi and Bo Jin and Jianying Zhou and Xian-qiao Jin},
  journal={Zhonghua zhong liu za zhi [Chinese journal of oncology]},
  year={2011},
  volume={33 11},
  pages={
          854-9
        },
  url={https://api.semanticscholar.org/CorpusID:34879518}
}
  • B. HanQ. Xiu X. Jin
  • Published in Zhonghua zhong liu za zhi… 1 November 2011
  • Medicine
  • Zhonghua zhong liu za zhi [Chinese journal of oncology]
Compared with TC alone treatmrnt, TC combined with endostar treatment can reduce the risk of disease progression at early time (24 weeks), increase the ORR, and can be used as first-line treatment for advanced NSCLC.
View on PubMed
doi.org
16 Citations
Highly Influential Citations
1
Background Citations
2

16 Citations

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study

The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated.

Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis

A systematic review and quantitative analysis of randomized clinical trials of patients with cancer failed to find a significant association between PFS and HRQoL in cancer clinical trials, raising questions regarding the assumption that interventions prolonging PFS also improve HRQeL in patients withcancer.

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

It is suggested that ICI-chemo is associated with potentially longer survival, better cost-effectiveness outcomes, and comparable safety profiles than anti-angio-chemo.

Long‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer

Phase II‐III trials in patients with untreated and previously treated locally advanced or non‐small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum‐based…

Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers.

Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.

Angiogenesis in tumorigenesis and the possible rationale for the synergy between angiogenesis inhibitors and CT In 1971

The role of angiogenesis in tumor growth and as a therapeutic target is reviewed, several agents that are either in use or under development for the treatment of patients with NSCLC are summarized, and the challenges and outlook for antiangiogenic agents when combined with CT are emphasized.

Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer.

The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control.

Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer

The combination of angiogenic agents with chemotherapy in the treatment of NSCLC is reviewed to show whether the combination schedule may be an important reason that has so far been overlooked in clinical trials.

Synergistic effects of the combination of Endostar and radiotherapy against hepatocellular carcinoma in a mouse model

A synergistic effect of Endostar combined with RT against HCC in vivo and in vitro is demonstrated, and the pathways involved are studied to understand the mechanisms behind this effect.